Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAG regimen for newly diagnosed adult T-cell acute lymphoblastic leukemia/T-lymphoblastic lymphoma
ChiCTR2000032101Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine, aclarubicin and granulocyte colony-stimulating factor in t-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete remission plus complete remission with incomplete hematologic recovery after one cycle. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
cytarabineaclarubicingranulocyte colony-stimulating factor
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on ChiCTR2000032101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032101.